Several studies demonstrate that finerenone, a non-steroidal mineralocorticoid receptor antagonist, improves cardiorenal outcomes in patients with CKD and type 2 diabetes with a manageable hyperkalemia risk and a reduction in hypokalemia (Bakris et al., 2019; Ruilope et al., 2019). The gene discussed is NR3C2; the disease is chronic kidney disease.